FDA adopts ICH guidance on continuous manufacturing

02 Mar 2023
endpts.com
After completing all four steps of the ICH’s guideline process, the FDA joined with its European regulatory colleagues in adopting this latest quality-related guideline on continuous manufacturing, known as Q13. The 42-page guidance , which has been in the works since 2018, clarifies continuous manufacturing concepts, describes the various scientific approaches that can be used, and presents regulatory considerations specific to this type of manufacturing for both drug substances and finished products. ICH noted that the guidance focuses on continuous manufacturing systems where two or more unit operations are directly connected, as well as guidance on the development, operation and management of continuous manufacturing systems. Drugmakers initially sought tweaks to the ICH guidance in Dec. 2021, with some seeking more clarity on how it would align with prior FDA draft guidance. An FDA spokesperson told Endpoints that this latest ICH guidance should be read in tandem with other FDA guidance on continuous manufacturing. According to a report from US Pharmacopeia, continuous manufacturing is implemented by several larger pharmas and does have advantages in boosting output, increasing efficiency and reducing environmental impact. However, there are high startup costs with implementing the process, USP said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.